<DOC>
	<DOCNO>NCT00990327</DOCNO>
	<brief_summary>The purpose study see whether apadenoson effective adenosine use pharmacological stress agent myocardial SPECT-Imaging detect defect supply blood heart muscle ( myocardial perfusion defect ) . The study also look whether apadenoson well tolerate adenosine use SPECT-MPI .</brief_summary>
	<brief_title>Study Safety Efficacy Apadenoson Detection Myocardial Perfusion Defects Using SPECT MPI</brief_title>
	<detailed_description>Adenosine effective vasodilator use SPECT-Myocardial Perfusion Imaging ( SPECT-MPI ) . However , produce transient symptom poorly tolerate subject . PGxHealth design multi-center , randomize crossover , double-blind study compare safety effectiveness apadenoson adenosine ( AdenoscanÂ® ) SPECT-MPI . Subjects clinical candidate SPECT-MPI enrol undergo two sequential SPECT-MPI study . The first study use adenosine stress agent approximately 1300 subject . Eligible subject randomize 1:2 assignment ratio receive second SPECT-MPI use either adenosine apadenoson pharmacologic stress agent , goal obtain total 753 subject complete study . The similarity result two adenosine : adenosine stress test compare adenosine : apadenoson test assess efficacy . The incidence intensity commonly report side effect compare evaluate improve tolerability .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>High pretest probability CAD base ACC/AHA guideline relative risk , past medical h/o CAD Ingestion caffeinated methylxanthine food substance ( e.g . chocolate , cocoa ) within 24 hour receive apadenoson adenosine Treatment dipyridamole within 24 hour , theophylline , aminophylline , pentoxifylline within 72 hour ( 4 halflives , whichever long ) prior receive apadenoson adenosine Acute MI , new onset ischemia PCI within 30 day prior SPECTMPI either Period 1 Period 2 ; CABG within 90 day prior SPECTMPI either Period 1 Period 2 Active severe asthma severe chronic obstructive pulmonary disease ( COPD ) , Investigator 's opinion , place subject risk severe bronchoconstriction History evidence clinically significant cardiac condition rhythm disorder , absence function permanently implant pacemaker Hemodynamically significant valvular disease , outflow tract obstruction , uncontrolled severe hypertension Current significant medical , surgical , psychiatric , illness pathology could potentiate adverse pharmacological event associate investigational drug Subject past medical history hepatitis B C , recent hepatitis A Pretreatment hypotension ( systolic BP &lt; 90 mm Hg ) tachycardia ( HR &gt; 100 bpm ) Known history cerebral vascular accident suspect transient ischemic attack within 30 day prior sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Myocardial Perfusion Imaging</keyword>
</DOC>